Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Strata Critical Medical, Inc.
Bear Case (25th pct.)
29.8% vs price
Base Case (Median)
30.3% vs price
Bull Case (75th pct.)
87.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| PE Comparable | $11.38 | 144.3% | Medium (25%) |
| Graham Number | $6.03 | 29.5% | Medium (40%) |
| EV/EBITDA | $6.07 | 30.2% | Medium (20%) |
Based on 3 out of 7 methods, SRTA appears undervalued at the current price of $4.66. The base case fair value of $6.07 implies 30.3% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.